On Monday, May 4, the next meeting of the Transparency Council.
AOTMiT: What will the Transparency Council address on May 4?
Published April 28, 2026 08:59
Źródło: AOTMiT
The agenda includes:
- Preparation of a position paper on the evaluation of the drug Lokelma (sodium zirconium cyclosilicate) for the indication: treatment of hyperkalemia in adult patients in the course of: chronic kidney disease grade 3a-5, in patients taking renin-angiotensin-aldosterone system inhibitor (ACEi/ARB) drugs or lack of use of these drugs; chronic heart failure, in patients taking renin-angiotensin-aldosterone system inhibitor (ACEi/ARB/ARNi) drugs and/or mineralocorticoid receptor antagonists (MRAs) or lack of use of these drugs.
- Preparation of a position paper on the evaluation of the drug Kimmtrak (tebentafuspum) under the drug program B.163.FM. "Treatment of patients with uveal melanoma (ICD-10: C69, C69.3, C69.4)".
- Preparation of a position paper on the evaluation of the drug Voraxaze (glucarpidasum) under drug program B.X "Elimination of toxic plasma methotrexate levels in adults and children (ICD-10: T45.1)".
- Preparation of an opinion on the appropriateness of amendments to the drug program B.38 "Treatment of low-grade children with chronic renal failure (ICD-10 N18)".
- Preparation of an opinion on the active substance enoxaparinum natricum for the off-label indication: prevention and treatment of venous thromboembolism in pregnant and postpartum women.
- Preparation of an opinion on the active substance nadroparinum calcicumwe in the off-label indication: prevention and treatment of venous thromboembolism in pregnant and postpartum women.
Source: AOTMiT
